The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
|Articles|February 6, 2023
POLL: Are You Attending South Beach Symposium?
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, improving patient outcomes.
- Targeted therapies and immunotherapies offer new hope, with molecular profiling and advanced imaging enabling precise treatment planning.
Click here to answer this week's poll.
Advertisement
Are You Attending South Beach Symposium?
If you can't attend South Beach Symposium,
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5